There were 876 press releases posted in the last 24 hours and 442,524 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
NeuroRx Announces Dosing of First Patient with ZYESAMI™ in P2/3 Clinical Study for the Treatment of Moderate and Severe COVID-19 (AVICOVID-2)

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image